title: Design evaluation and optimization for models of hepatitis C viral dynamics.
abstract: Mathematical modeling of hepatitis C viral (HCV) kinetics is widely used for understanding viral pathogenesis and predicting treatment outcome. The standard model is based on a system of five non-linear ordinary differential equations (ODE) that describe both viral kinetics and changes in drug concentration after treatment initiation. In such complex models parameter estimation is challenging and requires frequent sampling measurements on each individual. By borrowing information between study subjects, non-linear mixed effect models can deal with sparser sampling from each individual. However, the search for optimal designs in this context has been limited by the numerical difficulty of evaluating the Fisher information matrix (FIM). Using the software PFIM, we show that a linearization of the statistical model avoids most of the computational burden, while providing a good approximation to the FIM. We then compare the precision of the parameters that can be expected using five study designs from the literature. We illustrate the usefulness of rationalizing data sampling by showing that, for a given level of precision, optimal design could reduce the total number of measurements by up 50 per cent. Our approach can be used by a statistician or a clinician aiming at designing an HCV viral kinetics study.
authors.affiliation: Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545, USA. jeremie.guedj@gmail.com
authors.forename: Jeremie
authors.initials: J
authors.lastname: Guedj
authors.forename: Caroline
authors.initials: C
authors.lastname: Bazzoli
authors.forename: Avidan U
authors.initials: AU
authors.lastname: Neumann
authors.forename: France
authors.initials: F
authors.lastname: Mentré
mesh_terms: D003198:Computer Simulation; D016174:Hepacivirus / Q000502:physiology*; D019698:Hepatitis C, Chronic / Q000097:blood / Q000188:drug therapy / Q000821:virology*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008954:Models, Biological; D015233:Models, Statistical; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011994:Recombinant Proteins; D012107:Research Design
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a